It elevates CYP7A1/CYP8B1 expression in murine NAFLD models, activating FXR-SHP/FGF-dependent pathways to suppress fatty acid synthesis, which reduces lipid droplet accumulation and triglyceride content in both OA/PA-induced HepG2 cells and primary hepatocytes [118]. The gene discussed is CYP7A1; the disease is metabolic dysfunction-associated steatotic liver disease.